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HIV-1 Nef triggers down-regulation of cell-surface MHC-I by assembling a Src family kinase (SFK)-ZAP-70/Syk-PI3K
cascade. Here, we report that chemical disruption of the Nef-SFK interaction with the small molecule inhibitor 2c blocks
assembly of the multi-kinase complex and represses HIV-1–mediated MHC-I down-regulation in primary CD4 T-cells.
2c did not interfere with the PACS-2–dependent trafﬁcking of Nef required for the Nef-SFK interaction or the AP-1 and
PACS-1–dependent sequestering of internalized MHC-I, suggesting the inhibitor speciﬁcally interfered with the Nef-SFK
interaction required for triggering MHC-I down-regulation. Transport studies revealed Nef directs a highly regulated
program to down-regulate MHC-I in primary CD4 T-cells. During the ﬁrst two days after infection, Nef assembles the
2c-sensitive multi-kinase complex to trigger down-regulation of cell-surface MHC-I. By three days postinfection Nef
switches to a stoichiometric mode that prevents surface delivery of newly synthesized MHC-I. Pharmacologic inhibition
of the multi-kinase cascade prevents the Nef-dependent block in MHC-I transport, suggesting the signaling and
stoichiometric modes are causally linked. Together, these studies resolve the seemingly controversial models that describe
Nef-induced MHC-I down-regulation and provide new insights into the mechanism of Nef action.
INTRODUCTION
After infection by HIV-1, the acute viremia induces an im-
mune response that includes the development of anti-HIV
CD8 cytotoxic T lymphocytes (CTLs) (Gandhi and Walker,
2002). Though a signiﬁcant number of the circulating CTL
population is directed against HIV-1–infected cells, the virus
escapes the adaptive immune response, establishing reser-
voirs in numerous cell types that can resist highly active
antiretroviral therapy (HAART) (Stevenson, 2003). During
disease progression, the HIV-1 viral load increases greatly,
destroying most of the CD4 lymphocytes, leaving patients
increasingly susceptible to opportunistic infections (Douek
et al., 2003).
The adaptive immune response requires members of
the class I major histocompatibility complex (MHC-I) to
present viral antigens on the surface of infected cells,
which destroys the infected cell by the cytolytic, apopto-
sis-inducing actions of CTLs (Lieberman, 2003). Large
DNA viruses, including herpesviruses and poxviruses,
possess a large collection of immune evasive genes that
are expressed in a coordinated manner to target nearly
every step in the biosynthesis, assembly, transport, and
cell-surface localization of MHC-I molecules (Yewdell and
Hill, 2002; Peterlin and Trono, 2003). By contrast, HIV-1
relies on the single 27-kDa N-myristoylated early gene
product Nef to down-regulate MHC-I (Peterlin and
Trono, 2003). Nef is required for the onset of AIDS and
can affect cells in many ways, including alteration of T-cell
activation and maturation, subversion of the apoptotic
machinery, and the down-regulation of cell-surface mol-
ecules, notably CD4 and MHC-I (Fackler and Baur, 2002).
Down-regulation of CD4 through the clathrin/AP-2 path-
way to lysosomes eliminates interference of the viral re-
ceptor with HIV-1 envelopment or release. Down-regula-
This article was published online ahead of print in MBoC in Press
(http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E10–05–0470)
on August 4, 2010.
# These authors contributed equally to this work.
Address correspondence to: Gary Thomas (thomasg@ohsu.edu).
© 2010 J. D. Dikeakos et al. This article is distributed by The Amer-
ican Society for Cell Biology under license from the author(s). Two
months after publication it is available to the public under an
Attribution–Noncommercial–Share Alike 3.0 Unported Creative
Commons License (http://creativecommons.org/licenses/by-nc-
sa/3.0).
3279tion of cell-surface MHC-I molecules encoded by the
HLA-A and -B loci to paranuclear TGN/endosomal com-
partments mediates the ability of HIV-1 to evade the
CD8 immune surveillance system (Blagoveshchenskaya
et al., 2002; Tomiyama et al., 2002; Yang et al., 2002; Peter-
lin and Trono, 2003).
Two models—here referred to as the “signaling” and
“stoichiometric” down-regulation pathways—are currently
used to explain the molecular basis of Nef-mediated MHC-I
down-regulation (see Hung et al., 2007). The “signaling”
model describes the sequential roles of three conserved Nef
sites in mediating MHC-I down-regulation. The pathway is
initiated by the EEEE65-dependent binding to the sorting
protein PACS-2, which targets Nef to the paranuclear
region, enabling PXXP75 to bind and activate a Golgi
region-localized Src Family Kinase (SFK). This Nef-SFK
complex then phosphorylates ZAP-70 (Syk in monocytes
and heterologous cells), forming a phosphotyrosine-based
docking motif that recruits class I PI3K by ligating the p85
regulatory subunit C-terminal SH2 domain. This multi-
kinase complex then triggers internalization of cell-sur-
face MHC-I through a clathrin-independent, ARF6-depen-
dent pathway (Blagoveshchenskaya et al., 2002; Hung et al.,
2007; Atkins et al., 2008). After internalization, Nef M20, located
within an amphipathic -helix, mediates the sequestering of
endocytosed MHC-I molecules into paranuclear compartments
(Blagoveshchenskaya et al., 2002; Hung et al., 2007; Chaudhry et
al., 2008). By contrast, the “stoichiometric” model envisions
that Nef mediates MHC-I down-regulation by acting solely via
a PI3K-independent pathway that diverts newly synthesized
MHC-I molecules to degradative compartments by an M20-
and AP-1–dependent mechanism (Kasper and Collins, 2003;
Roeth et al., 2004; Kasper et al., 2005). However, an alternative
interpretation of the stoichiometric model suggests Nef binds
endocytosed MHC-I but the underlying mechanism was not
described (Roeth et al., 2004; Noviello et al., 2008). While the
stoichiometric model suggests the importance of Nef M20 in
mediating MHC-I down-regulation—a ﬁnding consistent with
both models—it fails to address the roles of EEEE65 and the
PXXP75 site within the polyproline helix.
The binding of HIV-1 Nef to the SH3 domains of SFKs
requires PXXP75 and an adjacent hydrophobic pocket, which
anchors the SFK on Nef (Lee et al., 1995). The determination
that Nef can bind and directly activate a subset of SFKs
together with the conservation of the SH3 domain binding
site across various Nef alleles (Choi and Smithgall, 2004;
Trible et al., 2006) suggests the Nef-SFK interaction is re-
quired for disease progression, including AIDS-like disease
in animal models and assembly of the SFK-ZAP-70/Syk-
PI3K multi-kinase complex, which triggers MHC-I down-
regulation in primary CD4 T-cells and promonocytic cells
(Hanna et al., 1998; Hung et al., 2007). These ﬁndings suggest
that targeting the assembly of the multi-kinase complex may
represent an attractive approach to inhibiting AIDS progres-
sion. The ability of isoform-speciﬁc class I PI3K kinase in-
hibitors to repress Nef-induced MHC-I down-regulation in
primary CD4 T-cells supports this possibility (Hung et al.,
2007; Atkins et al., 2008). Alternatively, small molecule in-
hibitors that disrupt the binding of Nef to one or more of the
kinases that form the multi-kinase complex would inhibit
Nef action without disrupting the activity of cellular kinases
that may be required for host cell function.
Here we report that small molecule disruption of Nef-SFK
binding represses MHC-I down-regulation in HIV-1–in-
fected primary CD4 T-cells by interfering with formation
of the multi-kinase complex. We further show that Nef-
induced MHC-I down-regulation in primary CD4 T-cells is
manifest by the sequential action of the signaling mode,
which lasts for more than two days after infection, followed
by the stoichiometric mode by three days postinfection.
Interference with the multi-kinase complex that triggers the
signaling mode disrupts the subsequent stoichiometric block
in MHC-I transport, suggesting the two modes are caus-
ally linked. These studies challenge the current dogma of
Nef-mediated MHC-I down-regulation (Hansen and Bou-
vier, 2009) and suggest Nef orchestrates a highly regu-
lated molecular program consisting of the sequential use
of signaling followed by stoichiometric modes to evade
immune surveillance.
MATERIALS AND METHODS
Cells, Viruses, and Plasmids
293T, A7, BSC-40, HeLa-CD4,H 9C D 4  T-cells, and CEM T-cells were
cultured as described (Hung et al., 2007). Peripheral blood was obtained from
healthy HLA-A*0201 volunteers by leukapheresis or venipuncture using
protocols approved by the OHSU Institutional Review Board (protocols
IRB00004039 and IRB00002251) or by the International Medical Center of
Japan and the Kumamoto University Ethical Committee. Primary human
CD4 T-cells were isolated as described (Hung et al., 2007) and cultured in
RPMI 1640 containing 10% FBS and supplemented with IL-2 (50 U/ml;
Sigma) and 1 g/ml PHA (Sigma, St. Louis, MO) before infection. HIV-1NL4-3,
vaccinia virus (VV), and vaccinia recombinants expressing FLAG-tagged Nef
(Nef/f, C-terminal epitope tag), NefAXXA/f, NefAXXA-PI3K*, Hck, Src, or
ZAP-70, and HIV pseudotyped viruses NL4-3G/P-EGFP (titer  4.5  107
IFU/ml) and NL4-3G/P-EGFP/Nef (titer  2.1  107 IFU/ml) were grown
and titered by marker expression as described (Blagoveshchenskaya et al.,
2002; Hung et al., 2007). Adenoviruses expressing HA-tagged PACS-1 or
PACS-2 were described previously (Blagoveshchenskaya et al., 2002; Simmen
et al., 2005). Nef-eYFP, NefAXXA-eYFP and pPTEN were previously described
(Hung et al., 2007) and pmaxGFP was obtained from Dharmacon (Boulder,
CO).
Inhibitors, siRNAs, qRT-PCR, and Kinase Assays
PI-103 (Calbiochem, San Diego, CA) and 2c (2,4-dihydroxy-5-(1-methoxy-2-
methylpropyl)benzene-1,3-dialdehyde, (Kyowa Hakko Kirin Co., Tokyo, Ja-
pan) were used as indicated. 2c toxicity was determined by MTT (Invitrogen,
Carlsbad, CA) according to manufacturer’s instructions. Control (nonspeciﬁc)
siRNA and siRNAs speciﬁc for Hck, Lyn, Src, PACS-1, PACS-2, or the 1A
subunit of AP-1 (Smartpool, Dharmacon) were nucleofected (Amaxa, Gaith-
ersburg, MD) into cells according to manufacturer’s instructions. RNA was
puriﬁed from H9 cells nucleofected with siRNAs as indicated in ﬁgure
legends using the RNeasy kit (Qiagen, Valencia, CA) according to manufac-
turer’s instructions. cDNA was reverse transcribed from RNA using the
random decamers from the RETROscript Kit (Ambion, Austin, TX) via man-
ufacturer’s instructions. Utilizing commercially-available Hck, Lyn, and Src
primers (Qiagen) and SYBR green qPCR reagent (SA-Biosciences, Frederick,
MD), q-PCR was conducted on a StepOnePlus Real-time PCR system (Ap-
plied Biosciences, Foster City, CA). PI3K assays were performed as described
(Atkins et al., 2008). In vitro Hck kinase assays were performed as described
(Emert-Sedlak et al., 2009).
Flow Cytometry and Immunoﬂuorescence Microscopy
For ﬂow cytometry, cells were processed as described (Hung et al., 2007;
Atkins et al., 2008) and stained using the following antibodies: anti-MHC-I
(W6/32), anti-HLA-A2 (BB7.2, BD, San Jose, CA), anti-CD4-APC (Biolegend,
San Diego, CA), or anti-p24-FITC (Virostat, Portland, ME) as indicated in
legends. PE-conjugated donkey anti-mouse IgG (Jackson IR, West Grove, PA)
was used to stain MHC-I– and HLA-A2–positive cells. Isotype-matched an-
tibodies (Serotec, Raleigh, NC) were used as negative controls. Samples were
processed on a FACSCalibur (BD) as described (Atkins et al., 2008) and data
analyzed using FCS express (De Novo Software, Los Angeles, CA). For
immunoﬂuorescence microscopy, cells were processed as indicated in legends
and processed for immunoﬂuorescence as described (Atkins et al., 2008).
Confocal images were captured as described (Atkins et al., 2008) and colocal-
ization of Nef-eYFP with Golgin-97 was quantiﬁed morphometrically using
Imaris 7.0. A mask for each ﬁeld of cells was generated based on the ﬂuores-
cent signal of Golgin-97 and the percent colocalization of Golgin-97 with
Nef-eYFP was determined and presented as the mean  SD from at least 20
cells per condition.
Immunoprecipitation, Western Blot, and Antibody Uptake
Cells infected with the indicated VV recombinants were harvested as de-
scribed (Atkins et al., 2008). Where indicated, cells were treated with the
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were immunoprecipitated with mAb M2-agarose (Sigma), and associated
proteins were detected by Western blot. The following antibodies were ob-
tained as indicated: mAb HA.11 (Covance, San Diego, CA); anti-Hck, anti-Lyn
(Santa Cruz, Santa Cruz, CA); anti-p85, anti-Src, anti-ZAP-70 (Upstate, Bed-
ford, MA); anti-phospho292ZAP-70 (BD); anti-Akt, anti-pAkt, anti-His6, anti-
PTEN, anti-cleaved caspase-3 (Cell Signaling, Danvers, MA); anti-actin
(Chemicon, Bedford, MA); anti-Nef #2949 (obtained through NIH AIDS Re-
search and Reference Reagent Program), anti-MHC-I K455 (provided by K.
Fru ¨h, OHSU), W6/32 and HC10 (provided by D. Johnson, OHSU); anti-AP-1
1A subunit (provided by L. Traub, University of Pittsburgh), AP-1 (Sigma),
anti-PACS-1 (703), anti-PACS-2 (Atkins et al., 2008). Antibody uptake using
mAb W6/32 was performed as described (Blagoveshchenskaya et al., 2002).
NMR Spectroscopy
The cDNA encoding consensus nef (obtained from the NIH AIDS Research
and Reference Reagent Program) was His6-tagged, inserted into pET21 vector
(EMD chemicals, San Diego, CA), and protein was expressed in Rosetta 2
(DE3) E. coli, cultured in modiﬁed minimal medium using 15NH4Cl as the sole
nitrogen source, and induced with 0.4 mM IPTG at 18°C for 16 h. Soluble
forms of His6-tagged Nef proteins were puriﬁed over a Ni2-NTA column
(GE Healthcare, Uppsala, Sweden) and subsequent gel-ﬁltration on a Super-
dex200 26/60 column (GE Healthcare) equilibrated with 25 mM sodium
phosphate buffer (pH 7.5), 150 mM NaCl, 1 mM DTT, and 0.02% sodium
azide. Two-dimensional (2D) 1H-15N heteronuclear single quantum coher-
ence (HSQC) experiments (Bodenhausen and Ruben, 1980) were performed at
27°C on a Bruker Avance 700 MHz spectrometer equipped with a 5-mm,
triple resonance, and z-axis gradient cryoprobe. The 1H-15N HSQC spectrum
of free Nef was obtained using a 80-M uniform 15N-labeled Nef sample in 10
mM HEPES, 10 mM DTT, 100 mM NaCl, and 5% (vol/vol) D2O (pH 8.0). A
series of 1H-15N HSQC spectra were acquired to monitor chemical shift
changes upon addition of aliquots of a 10-mM 2c stock solution, dissolved in
DMSO, to the Nef sample. The Nef:2c molar ratios of the solutions were 1:0,
1:0.6, 1:1.75, 6.25, and 12.5. A control series of 1H-15N HSQC spectra were also
obtained after adding the same amounts of DMSO without 2c to the free Nef
sample. In this series, in contrast to the titration with the 2c solution, minimal
spectral changes occurred (data not shown), conﬁrming that the changes after
addition of 2c were indeed caused by this organic molecule and not the
solvent.
Transport Assay and Endo H Treatment
H9 cells were infected with Nef or Nef pseudotyped HIV-1NL4-3 viruses for
24, 48, or 72 h. After infection, cells were subjected to pulse-chase/surface
biotinylation as described (Blagoveshchenskaya et al., 2002). Brieﬂy, to IP with
HC10, cells were lysed in m-RIPA [1% NP-40, 1% sodium deoxycholate, 150
mM NaCl, 50 mM Tris-HCl (pH 8.0)] and then heated for1ha t55°C to
denature MHC-I proteins. To IP with BB7.2, cells were lysed in PBS (pH 7.2)
containing 1% NP-40. Bound MHC-I proteins were eluted from protein A
sepharose beads (Sigma) by boiling in TBS, 5% SDS, 2% NP-40, and 2%
sodium deoxycholate. One-third of the eluate was used to assess total MHC-I
while the rest was incubated with streptavidin agarose (Pierce, Rockford, IL)
to capture biotinylated MHC-I. For Endo H treatment, MHC-I was eluted by
boiling in 10 mM Tris-HCl (pH 7.4) containing 1% SDS, precipitated with
acetone and resuspended in glycoprotein denaturation buffer (NEB, Ipswich,
MA) and digested with 10 U of Endoglycosidase H for1ha t37°C. Samples
were separated by SDS-PAGE and processed using Amplify (GE Healthcare).
Quantiﬁcation was performed using NIH Image J.
Protein Interaction Assays
Plasmids expressing GST, GST-MHC-I CDNefLL/AA (provided by J. Guatelli,
UCSD), His6-HcK∧OR GST-Nef (strain NL4-3), were transformed in BL21 E.
coli and cultures were induced with 1 mM IPTG (Calbiochem) for4ha t37°C.
Bacterial pellets were resuspended in lysis buffer [50 mM Tris (pH 7.6), 1.5
mM EDTA, 100 mM NaCl, 0.5% Triton X-100, 0.1 mM DTT, 10 mM MgCl2]
containing protease inhibitors (0.5 mM PMSF and 0.1 M each of aprotinin,
E-64, and leupeptin), lysed using a French Press (Aminco, Rockville, MD) and
incubated with GST-sepharose (GE Healthcare). For the interaction with
GST-MHC-I CDNefLL/AA, A7 cells were lysed in 50 mM Tris-HCl (pH 8.0),
1% Triton X-100, 5 mM EDTA, 150 mM NaCl, 10 mM MgCl2 with protease
inhibitors (0.5 mM PMSF and 0.1 M each of aprotinin, E-64, and leupeptin).
A7 lysates were added to GST-Sepharose bound to the proteins of interest
overnight at 4°C. The resin was incubated or not with 20 M 2c for one hour,
washed three times in lysis buffer and once in 50 mM Tris (pH 8.0), and
resuspended in SDS-PAGE sample buffer. For the His6-Hck interaction with
GST-Nef, the proteins were mixed at a 2:1 ratio (Hck:Nef) for 30 min at 4°C in
binding buffer [0.1% NP-40, 0.1 mM EDTA, 20 mM Tris (pH 7.9), 150 mM
NaCl] containing the indicated concentrations of 2c. After incubation, GST-
Sepharose was added and subsequently washed three times in binding buffer
and resuspended in SDS-PAGE sample buffer.
RESULTS
HIV-1 Nef Uses a Subset of SFKs to Trigger MHC-I
Down-Regulation
Formation of the SFK-ZAP70/Syk-PI3K multi-kinase com-
plex is initiated by the PXXP75-dependent binding of Nef to
the SH3 domain of a Golgi region-localized SFK, directly
activating the kinase (Hung et al., 2007). Of the seven known
SFKs only a subset—Hck, Lyn, and Src—can be directly
activated after Nef binding and are found in the Golgi
region, suggesting one or more of these kinases mediate
MHC-I down-regulation (Matsuda et al., 2006; Trible et al.,
2006; Hiyoshi et al., 2008; Pulvirenti et al., 2008). To test this,
H9 CD4 T-cells treated with siRNAs speciﬁc for Hck,
Lyn, or Src (Figure 1A and supplemental Figure S1) were
infected with recombinant viruses expressing Nef and the
extent of MHC-I down-regulation was determined. Nef-
induced MHC-I down-regulation was slightly repressed
by siRNA knockdown of Hck alone but blocked by knock-
down of Hck, Lyn, and Src together. The data suggest that
Hck, Lyn, and Src function redundantly in Nef-induced
MHC-I down-regulation.
Small Molecule Inhibition of the Nef-SFK Interaction
The determination that Nef assembles a multi-kinase com-
plex to trigger MHC-I down-regulation suggests this path-
way can be selectively targeted pharmacologically. Indeed,
isoform-speciﬁc class I PI3K inhibitors repress Nef-induced
MHC-I down-regulation in primary CD4 T-cells (Hung et
al., 2007; Atkins et al., 2008). An alternative approach would
be to block protein-protein interactions required for complex
assembly without affecting cellular enzyme activity directly.
The characterized binding of Nef to SFK SH3 domains rep-
resents an ideal target for this type of inhibitor (Arold et al.,
1997). One candidate compound, 2c (supplemental Figure
S2), is a derivative of the compound UCS15A that disrupts
the PXXP-dependent binding of Sam68 to Src (Oneyama et
al., 2003). To test whether 2c disrupts Nef-SFK binding, we
treated H9 CD4 T-cells coexpressing ﬂag-tagged Nef
(Nef/f) and Hck with increasing concentrations of 2c. Hck
was used because it binds Nef with higher afﬁnity than other
SFKs and Nef can assemble Hck into the multi-kinase com-
plex (Hung et al., 2007; Atkins et al., 2008). Coimmunopre-
cipitation analysis showed 2c repressed the interaction be-
tween Nef and Hck in a dose-dependent manner as well as
repressed the interaction with Lyn or Src (Figure 1B and
supplemental Figure S3). Next, we incubated GST-Nef and
His6-Hck with increasing concentrations of 2c and found
that 2c disrupted Nef-Hck binding in a dose-dependent
manner (Figure 1C). To determine whether the ability of 2c
to inhibit Nef-SFK binding also blocked Nef-induced SFK
activation, we incubated recombinant, puriﬁed Nef, and
Hck with increasing concentrations of 2c and measured the
resulting Nef-induced Hck activity using a FRET-based in
vitro kinase assay. Under these assay conditions, activation
of Hck is dependent upon Nef (Emert-Sedlak et al., 2009). As
shown in Figure 1D, 25 M 2c substantially repressed Nef-
dependent Hck activity without affecting Hck in the absence
of Nef. High 2c concentrations (100 M), however, directly
inhibited Hck activity. These ﬁndings suggest 2c has a bi-
modal effect on Hck activity; at low concentrations 2c dis-
rupts Nef-induced kinase activity, whereas high concentra-
tions of 2c inhibit Hck directly.
The ability of 2c to selectively inhibit Nef-induced Hck acti-
vation suggested 2c may bind Nef directly, thereby affecting
Hck activity. Accordingly, 1H-15N HSQC NMR analysis of the
interaction of 2c with recombinant Nef in solution revealed 2c
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Vol. 21, October 1, 2010 3281Figure 1. 2c interferes with Nef:SFK binding. (A) H9 CD4 T-cells were nucleofected (Amaxa) on days 1 and 3 with pmaxGFP and
nonspeciﬁc siRNA or siRNAs that target Hck, Lyn, or Src alone or in combination. On day 4 cells were infected with VV:WT (gray ﬁlled) or
VV:Nef (lines, unﬁlled) (moi  10, 8 h), and analyzed by ﬂow cytometry using mAb W6/32 as described in experimental procedures. MFI:
NS siRNA (WT  167, Nef  99.5); Nef  Hck siRNA  120;  Lyn siRNA  103;  Src siRNA  117;  Hck, Lyn, Src  169. MFI, mean
ﬂuorescence intensity. (B) H9 cells were coinfected with VV:WT, VV:Nef/f or NefAXXA/f (moi  10, 8 h) and VV:Hck (moi  2, 8 h) and
treated with 10, 20, or 50 M 2c for 4 h before harvest. Nef/f proteins were immunoprecipitated, and coprecipitating Hck was detected by
Western blot. (C) GST-Nef was incubated with His6-Hck and treated with increasing concentrations of 2c. GST-Nef was captured, and bound
His6-Hck was quantiﬁed using NIH Image J. Accordingly, nonspeciﬁc binding of GST to His6-Hck was subtracted and values were
normalized to the binding of GST-Nef to His6-Hck in the absence of 2c. Each condition was assayed in triplicate, and results are presented
as the mean  SD. (D) Hck alone (gray bars) or Hck plus Nef (black bars) were treated with increasing concentrations of 2c. The resulting
Hck enzyme activity was measured using a ﬂuorometric assay and expressed relative to 100% control activity. Each condition was assayed
in quadruplicate and results are presented as the mean  SD. (E) Superposition of 1H-15N HSQC spectra of Nef in the absence (blue) and
presence (red) of 2c. The 1H-15N HSQC spectra were recorded on 80 M uniform 15N-labeled Nef samples at 27°C in the absence (blue) and
presence (red) of 1 mM 2c (1:12.5 M ratio of Nef to 2c). All assignable amide resonances (J. Jung, I.-J.L. Byeon, J. Ahn, and A.M. Gronenborn,
unpublished data) that exhibit chemical shift changes 0.06 ppm are labeled with residue name and number. The resonances of Y135,V 146,
and F185 are labeled only on the free Nef spectrum because the identiﬁcation of the bound resonances was not straightforward either due to
very large shift changes or severe line broadening beyond detection. The resonances of M79 (  0.041ppm) and T80 (  0.025ppm), which
are located immediately after the P72XXP75 motif, are also labeled. Concentrations of 2c as low as 48 M, representing a 1:0.6 M ratio of Nef
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nances of Nef (Figure 1E). These include relatively small chem-
ical shift changes (0.025–0.063ppm) at V74,M 79, and T80 located
within the Nef polyproline helix that binds the RT loop of SH3
domains on SFKs (Lee et al., 1995), suggesting 2c may inﬂuence
the conformation of the polyproline helix. The presence of
resonance overlap in the NMR spectra precluded more de-
tailed analysis involving the disordered regions of Nef such as
the N-terminal region preceding the polyproline helix and the
internal loop consisting of residues E149–K178. More pro-
nounced chemical shift changes (0.1ppm) were observed for
the resonances of Y135,K 144,V 146,K 184 (R184 in Figure 1F [PDB
ID:2NEF]), F185, and L189 which are clustered on the opposite
side of the SH3 domain binding site. Other residues in this
region such as V148,A 190,F 191,M 194, and E197, and L198 also
undergo substantial (0.06ppm) changes. These chemical shift
perturbations caused by the addition of 2c imply that 2c could
bind to the cleft formed by the central -sheet and the C-
terminal -helices of Nef, which may provide a good binding
pocket (Figure 1F). Together, these ﬁndings suggest 2c
may interfere with Nef-induced SFK activation most
likely by allosteric inhibition of SFK binding or possibly
by directly inﬂuencing the binding mode of the polypro-
line helix to SFKs or both.
2c Represses the Ability of HIV-1 to Down-Regulate
MHC-I
The 2c concentration range that selectively inhibited Nef-
dependent SFK activation showed no measurable cell toxic-
ity up to 60 M for two days, suggesting 2c could be tested
in culture (Figure S4, panel A). Accordingly, we treated H9
cells expressing Nef-eYFP with 2c or the class I PI3K inhib-
itor PI-103, which speciﬁcally blocks Nef-induced MHC-I
down-regulation (Hung et al., 2007), and measured cell-
surface MHC-I (Figure 2A). In agreement with earlier stud-
ies (Hung et al., 2007; Atkins et al., 2008), Nef-eYFP induced
an twofold down-regulation of MHC-I that was blocked
by PI-103. Similarly, 2c partially blocked MHC-I down-reg-
ulation. Next, we asked whether 2c could interfere with
HIV-1–induced MHC-I down-regulation in primary CD4
T-cells. We infected primary CD4 T-cells with HIV-1NL4-3
and treated the cultures with vehicle or 2c. At 8 d postin-
fection, the cells were analyzed for cell-surface HLA-A2 and
CD4 by ﬂow cytometry (Figure 2B). We found that 2c par-
tially blocked down-regulation of MHC-I but had no effect
on down-regulation of CD4, which is mediated by a class I
PI3K-independent pathway (Hung et al., 2007).
2c Disrupts Formation of the Multi-Kinase Complex
The ability of 2c to disrupt Nef-SFK binding as well as
HIV-1–induced MHC-I down-regulation suggested this
compound would disrupt assembly of the SFK-ZAP-70-
PI3K multi-kinase complex. Accordingly, we found that
2c blocked the ability of Nef to recruit class I PI3K activity
using an in vitro lipid kinase assay (Figure 3A). Moreover,
this result was not due to cell toxicity or induction of
apoptosis nor was it due to nonspeciﬁc inhibition of class
I PI3K as treatment of the immunoprecipitate with 40 M
2c had no effect on enzyme activity (supplemental Figure
S4, B and C and Figure 3A). The titration analysis of 2c on
Nef-induced Hck activation (Figure 1D) suggests 40 M
2c blocked Nef-induced PI3K stimulation by selective in-
hibition of Nef-induced SFK activation, whereas 100 M
2c may block Nef-induced PI3K stimulation by addition-
ally inhibiting SFK activation directly. The PI3K activity
results were supported by coimmunoprecipitation analy-
sis in which 2c inhibited formation of the multi-kinase
complex by disrupting the interaction of Nef with Hck,
phospho-ZAP-70 and the class I PI3K p85 regulatory sub-
unit (Figure 3B).
The ability of 2c to disrupt Nef-SFK binding did not
exclude the possibility that it may affect additional steps in
the MHC-I down-regulation pathway. We ﬁrst asked
whether 2c interfered with steps upstream of Nef-SFK bind-
ing. Accordingly, we found that 2c had no effect on the
Nef-PACS-2 interaction nor the PACS-2–dependent trafﬁck-
ing of Nef-eYFP to the paranuclear region, which is required
for Nef-SFK binding and Nef-induced MHC-I down-regula-
tion (Figure 3, C and D and Atkins et al., 2008).
Because Nef M20 mediates the interaction with AP-1
(Roeth et al., 2004) and is essential for sequestration of
MHC-I molecules after their internalization from the cell
surface (Blagoveshchenskaya et al., 2002), we tested
whether AP-1 was required in the last stage of this sig-
naling pathway. Accordingly, H9 cells knocked down for
AP-1A, PACS-2, or PACS-1 which is required for MHC-I
down-regulation but not for triggering PI3K stimulation
(Piguet et al., 2000; Atkins et al., 2008), were infected with
viruses expressing Nef or the NefAXXA-PI3K* chimera,
which rescues the inability of NefAXXA to down-regulate
MHC-I by overriding the requirement for assembly of the
SFK-ZAP-70-PI3K complex (supplemental Figure S5 and
Blagoveshchenskaya et al., 2002; Hung et al., 2007). The
ability of Nef or NefAXXA-PI3K* to down-regulate MHC-I
in cells knocked down for expression of PACS-2, PACS-1,
or AP-1A was assessed by antibody uptake to discern the
importance of each protein in steps upstream or down-
stream of PI3K stimulation (Figure 4A). Consistent with
our determination that Nef requires PACS-2 upstream of
PI3K (Atkins et al., 2008), siRNA knockdown of PACS-2
blocked MHC-I uptake by Nef but not by NefAXXA-PI3K*.
By contrast, siRNA knockdown of AP-1A or PACS-1
blocked MHC-I uptake induced by Nef and NefAXXA-
PI3K*, demonstrating AP-1 and PACS-1 act downstream
of PI3K stimulation.
To test potential effects of 2c on the later stages of this
pathway, we asked whether 2c interfered with the inter-
action between Nef and PACS-1 or AP-1. We determined
that 2c had no effect on the Nef-PACS-1 interaction (Fig-
ure 4B). Additionally, the interaction of AP-1 with Nef
M20 and the MHC-I cytosolic domain can be recapitulated
using the chimeric protein GST-MHC-I CD-NefLL/AA to
capture AP-1 from cytosol preparations (Noviello et al.,
2008). This chimera consists of Nef with an LL1653AA
substitution, which blocks the LL165-dependent binding to
adaptors, fused to the MHC-I cytosolic domain. We found
that 2c did not interfere with the ability of GST-MHC-I
CD-NefLL/AA to capture AP-1 (Figure 4C, left). Interest-
Figure 1 (cont). to 2c, revealed chemical shift changes between
15N-Nef and 2c. (F) Structural mapping of the chemical shift changes
in the 1H-15N HSQC spectrum of Nef induced by 2c onto the Nef
NMR structure (PDB ID: 2NEF, see (Grzesiek et al., 1997)). The
1H-15N-combined chemical shift changes were calculated using
	HN
2(N0.1)2, with HN and N the 1HN and 15N chem-
ical shift differences, respectively, between the free and 2c-bound
Nef protein spectrum. On a stereoview of the structure in ribbon
representation, sidechains of residues whose amide resonances ex-
hibit signiﬁcant changes are shown in stick representation and color
coded according to the size of the change: orange; 0.06–0.1 ppm,
and red; 0.1 ppm. Residues whose 1H-15N HSQC amide reso-
nances are only detectable/assignable in free Nef are colored in
magenta and the sidechains of the two prolines in the P72XXP75
region are shown in green.
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PACS-1 but not PACS-2, consistent with our determina-
tion that Nef requires PACS-1 subsequent to PI3K stimu-
lation to down-regulate MHC-I (Figure 4C, right). More-
over, similar to our ﬁndings with AP-1, 2c failed to
disrupt the interaction of GST-MHC-I CD-NefLL/AA with
PACS-1. To further evaluate whether 2c disrupts MHC-I
down-regulation downstream of PI3K stimulation, we re-
peated the antibody uptake experiment (Figure 4D). We
found that 2c blocked the ability of Nef but not NefAXXA-
PI3K* to down-regulate MHC-I, indicating 2c speciﬁcally
acts upstream of PI3K stimulation.
PTEN-Null CEM Cells Fail to Phenocopy Nef Action in
Primary CD4 or H9 Cells
Our results using primary CD4 T-cells and H9 cells suggest
2c disrupts HIV-1–mediated MHC-I down-regulation by in-
terfering with the ability of Nef to assemble the SFK-ZAP-
70/Syk-PI3K complex. This signaling pathway explains the
importance of the EEEE65 and PXXP75 sites, which trigger
MHC-I internalization and subsequent M20-mediated se-
questering of internalized MHC-I molecules (Blagovesh-
chenskaya et al., 2002; Hung et al., 2007). However, an alter-
nate model of MHC-I down-regulation, which largely relies
on CEM T-cells stably expressing MHC-I, envisions a PI3K-
independent pathway based largely on the M20-mediated
stoichiometric block of newly synthesized MHC-I molecules
en route to the cell surface (Kasper and Collins, 2003). We
therefore transfected CEM cells with plasmids expressing
PTEN alone or together with Nef (Figure 5A), and tested
whether 2c or PI-103 would repress MHC-I down-regula-
tion. Because transfected PTEN can be inhibited by oxida-
tion in leukemic cells, these experiments were conducted in
0.5 mM -mercaptoethanol (Silva et al., 2008). In contrast to
H9 cells or primary CD4 T-cells, both compounds failed to
repress MHC-I down-regulation in CEM cells (Figure 5B,
top), suggesting Nef may down-regulate MHC-I in CEM
cells by a mechanism different from it uses in H9 or primary
CD4 T-cells. Alternatively, the disparate ﬁndings may have
resulted from the dysregulated PI3K signaling inherent to
CEM cells, which would override the requirement for the
multi-kinase complex (Astoul et al., 2001). Indeed, many
leukemic cell lines such as CEM and Jurkat lack the tumor
suppressor PTEN, which is a lipid phosphatase that attenu-
ates PI3K signaling by dephosphorylating PIP3. Thus, loss of
PTEN results in constitutively elevated levels of PI3K/Akt
signaling characteristic of many tumor cell lines. Although
acute treatment of CEM or Jurkat cells with PI3K inhibitors
Figure 2. 2c represses HIV-1-induced down-
regulation of MHC-I but not CD4. (A) H9 cells
expressing eYFP (vector) or Nef-eYFP (Nef) for
24 h were treated or not with 20 M 2c (Nef  2c)
or 5 M of the class I PI3K inhibitor, PI-103
(Nef  PI-103) for another 16 h. At 40 h, cultures
were analyzed by ﬂow cytometry using W6/32.
MFI: vector  479, Nef  208, Nef  2c  312,
Nef  PI-103  444. Inset: Western blot showing
expression of Nef-eYFP and actin. (B) Parallel
cultures of primary CD4 T-cells were infected
with HIV-1NL4-3 and treated or not with 20 M2 c
at days 5 and 7 postinfection. At 8 d postinfection
the cells were stained with p24-FITC, BB7.2, and
CD4-APC and then analyzed for down-regula-
tion of HLA-A2 (top) and CD4 (bottom) by ﬂow
cytometry as described in Methods. MHC-I MFI:
uninfected  518, HIV  193, HIV  2c  301.
CD4 MFI: uninfected  413, HIV  25.1, HIV 
2c  25.2. Inset: Western blot showing expression
of Nef and actin.
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persistently elevated levels of PIP3 that mediate PI3K-stim-
ulated pathways even in the presence of PI3K inhibitors,
thereby conferring resistance to the effect of multi-kinase
complex inhibition (Hung et al., 2007). We therefore ex-
pressed PTEN alone or PTEN together with Nef (Figure 5A)
and determined that PTEN alone had little effect on the
cell-surface levels of endogenous MHC-I, which is expected
because this enzyme is normally expressed in CD4 T-cells
(Figure 5B, bottom). Reexpression of PTEN, however, re-
pressed the constitutively elevated PI3K/Akt signaling
present in CEM cells as determined by a decrease in active
Figure 3. 2c blocks the ability of Nef to assemble the multi-kinase complex. (A) H9 cells were infected with VV:WT, VV:NefAXXA/f, or
VV:Nef/f (moi  10, 8 h) and treated with 40 or 100 M 2c for 4 h (which showed no toxicity in this time frame, supplemental Figure S3,
b and c). Nef/f was immunoprecipitated and Nef-associated class I PI3K p85 regulatory subunit was detected by Western blot, and associated
PI3K activity was measured using an in vitro lipid kinase assay as described in Methods. As controls, 40 M 2c and 1 M PI-103 were
incubated with the eluted fraction for 10 min before kinase assay (in vitro samples). Each assay was measured in triplicate and results are
presented as the mean  SD. (B) Left: H9 cells were coinfected with VV:WT, VV:NefAXXA/f, or VV:Nef/f (moi  6, 8 h) and VV:ZAP70 (moi 
4, 8 h). Nef/f was immunoprecipitated and coprecipitating Hck, phospho-ZAP-70 and p85 were detected by Western blot. Right: The amount
of each Nef-associated kinase was quantiﬁed with Image J and presented numerically as the relative amount of Nef-associated kinase  20
M 2c. Error bars represent the mean  SD from 3 independent experiments. (C) H9 cells were coinfected with VV:Nef/f (moi  6 ,8h )a n d
VV:PACS-2 (moi  4, 8 h) and treated with 40 or 100 M 2c for 4 h before harvest. Nef/f was immunoprecipitated and coprecipitating PACS-2
was detected by Western blot. (D) Upper: HeLa cells expressing Nef-eYFP together with a control siRNA (NS) or PACS-2 siRNA (Western
blot of siRNA knockdown shown at bottom). Lower: HeLa cells expressing Nef-eYFP were treated with 20 M 2c for 16 h. Cells were stained
with anti-Golgin 97 (red) and visualized by confocal microscopy (scale bar, 10 m). Morphometric analysis was performed as described in
Methods. Error bars are presented as the mean  SD from at least 20 cells per condition and three independent experiments.
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replete CEM cells may be rescued in their ability to regulate
PIP3 levels and would thus be responsive to treatment with
PI3K inhibitors. Accordingly, reexpression of PTEN rescued
the ability of PI-103 or 2c to repress MHC-I down-regulation
in CEM cells, similar to that observed in primary CD4
T-cells or H9 cells (Figure 5B bottom and see Figure 2). These
results demonstrate that an intact PI3K regulatory network
is required to study PI3K-dependent steps in signaling path-
ways, including Nef-induced MHC-I down-regulation.
Nef Down-Regulates MHC-I by a PI3K-Triggered
Endocytic Pathway Followed by a Transport Block
Whereas aberrant phosphoinositide metabolism in CEM
cells can explain the confusion underlying the requirement
by Nef for the multi-kinase complex to down-regulate
MHC-I (Kasper and Collins, 2003; Schaefer et al., 2008), this
defect did not readily explain why some studies found that
Nef blocks delivery of newly synthesized MHC-I molecules
en route to the cell surface—the stoichiometric model—
whereas other studies found Nef relies on its ability to
assemble the multi-kinase complex to internalize and se-
quester MHC-I molecules following their delivery to the cell
surface—the signaling model. Although these disparate
ﬁndings were originally attributed to uncharacterized dif-
ferences in Golgi-to-cell-surface transport in T-cells versus
HeLa cells (Kasper and Collins, 2003), closer inspection of
the experimental paradigm revealed that the signaling
model assessed MHC-I transport at 7–44 h postinfection
while the stoichiometric model assessed ER-to-cell sur-
face transport of MHC-I at longer postinfection times
(Blagoveshchenskaya et al., 2002; Kasper et al., 2005; Hung et
al., 2007). We therefore conducted a time course to measure
the ability of Nef to impede cell surface delivery of newly
synthesized endogenous MHC-I molecules (Figure 6A). Par-
allel cultures of H9 cells infected for 24, 48, or 72 h with
pseudotyped HIV-1NL4-3 that either lack or express Nef were
subjected to pulse-chase/surface biotinylation to monitor
Figure 4. PACS-1 and AP-1 are required downstream of the 2c-sensitive multi-kinase complex. (A) Left: H9 cells were nucleofected with
pmaxGFP together with a control siRNA (NS) or siRNAs speciﬁc for PACS-1, PACS-2, or 1A. After 48 h, cells were infected with VV:WT,
VV:Nef, or VV:NefAXXA-P13K* (moi  10, 5 h). Cells were incubated with W6/32 (3 g/ml) for 30 min, chased for an additional 30 min, then
incubated with 0.5% acetic acid (pH 3.0) in 0.5M NaCl to remove surface antibody, ﬁxed, and processed for immunoﬂuorescence microscopy.
Scale bar, 10 m. Right: A portion of the cells from left were analyzed by Western blot for extent of siRNA knockdown. (B) H9 cells were
coinfected with VV:Nef/f (moi  6, 8 h) and VV:PACS-1 (moi  4, 8 h) and treated with 40 or 100 M 2c for 4 h before harvest. Nef/f was
immunoprecipitated, and coprecipitating PACS-1 was analyzed by western blot. (C) Left: GST-MHC-I CDNefLL/AA or GST was mixed with
A7 cell lysate, treated with 20 M 2c, and captured g or 1A subunits of AP-1 detected by Western blot. Right: Lysates from A7 cells
expressing HA-tagged PACS-1 or PACS-2 were incubated with GST-MHC-I CDNefLL/AA or GST, treated with 20 M 2c, and bound PACS
proteins detected by Western blot. (D) H9 cells were treated or not with 20 M 2c for 18 h and then infected with VV:WT, VV:Nef,
VV:NefAXXA, or VV:NefAXXA-P13K* (moi  10, 5 h). Cells were incubated with W6/32 (3 g/ml) for 30 min and then chased for an additional
30 min and processed for immunoﬂuorescence microscopy as described in the legend to panel A. Scale bar, 10 m.
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fection, Nef had no measurable effect on the transport of
newly synthesized MHC-I to the cell-surface. By 72 h postin-
fection, however, Nef markedly repressed MHC-I transport.
To test whether these results were speciﬁc to H9 cells or the
use of HC10, which recognizes denatured HLA-B and C
heavy chains, we repeated the pulse-chase/surface biotiny-
lation in primary CD4 T-cells using the conformation de-
pendent antibody, BB7.2, which recognizes HLA-A2. In
agreement with our ﬁndings in H9 cells, Nef had no appre-
ciable effect on cell-surface delivery of HLA-A2 for the ﬁrst
48 h postinfection in primary CD4 T-cells. Again, similar to
H9 cells, at 72 h postinfection Nef markedly repressed
HLA-A2 transport to the cell surface (Figure 6B).
To determine whether the switch in Nef-induced MHC-I
down-regulation was coupled with a change in MHC-I sta-
bility, H9 cells infected with Nef or Nef pseudotyped
HIV-1 for 24 or 72 h were pulse-labeled with [35S]Met/Cys
for 15 min and chased for up to 20 h. Immunoprecipitation
of endogenous MHC-I with HC10 showed that Nef had no
obvious effect on MHC-I stability at 24 or 72 h postinfection
(Figure S6). To assess whether Nef altered the rate of MHC-I
transport, the immunoprecipitates were subjected to en-
doglycosidase H (Endo H) digestion, which demonstrated
MHC-I molecules became Endo H resistant by 4 h postin-
fection irrespective of Nef expression or the time postinfec-
tion (Figure 6C). These ﬁndings suggest Nef does not im-
pede MHC-I transport from early secretory pathway
compartments nor does it markedly affect the stability of
endogenous MHC-I molecules.
The inability of Nef to block ER-to-cell surface transport of
MHC-I molecules for at least 48 h postinfection suggested
that for the ﬁrst two days Nef may down-regulate MHC-I by
triggering the multi-kinase–dependent internalization and
sequestering of MHC-I molecules from the cell surface. We
tested this possibility using antibody uptake. H9 cells were
infected with Nef or Nef pseudotyped HIV-1 for 48 or
72 h and then incubated with anti–MHC-I (W6/32) in the
absence or presence of 2c or PI-103. The cells were then
ﬁxed, permeabilized, and stained with a secondary antibody
to detect internalized MHC-I (W6/32) and with antibody
K455 to detect steady-state MHC-I (Figure 6D). In agreement
with the biotinylation analysis, at 48 h postinfection Nef
induced a marked increase in MHC-I internalization that
overlapped with the MHC-I post-ﬁx staining pattern. Treat-
ment of the cells with 2c or PI-103 blocked antibody uptake,
suggesting multi-kinase complex formation was required to
down-regulate MHC-I at these time points. By contrast, at
72 h postinfection Nef failed to induce W6/32 uptake de-
spite down-regulating MHC-I as determined by the K455
post-ﬁx staining pattern. Analysis by ﬂow cytometry re-
vealed that Nef reduced cell surface levels of MHC-I to a
similar extent at 48 h or 72 h postinfection (Figure 6E).
Together, these experiments suggest that Nef-induced
MHC-I down-regulation is manifest for two days by a Nef-
assembled PI3K signaling pathway that sequesters MHC-I
endocytosed from the cell-surface followed by a switch in
Nef action at day three to a stoichiometric mechanism that
prevents ER to cell surface transport of newly synthesized
MHC-I.
The Signaling Mode Is Required for the Switch to the
Stoichiometric Mode
The switch in Nef-induced MHC-I down-regulation from a
signaling-based pathway to a stoichiometric mechanism did
not appear to result from use of tumor cell lines, differences
in antibodies used to immunoprecipitate MHC-I, or levels of
Nef expression (see Figure 6). We therefore asked whether
Figure 5. CEM cells do not model primary CD4 T-
cells in Nef action. (A) Western blot analysis of PI3K-
dysregulated CEM cells rescued or not for PTEN. (B)
Top: CEM cells expressing eYFP (vector) or Nef-eYFP
(Nef) were treated or not with 20 M 2c (Nef  2c) for
16 h before analysis or 1 M PI-103 (Nef  PI-103) for
3 h before analysis in media containing 0.5 mM
ß-mercaptoethanol. Cells were analyzed by ﬂow cytom-
etry using W6/32 as described in Methods. MFI: vec-
tor  425, Nef  125, Nef  2c  123, Nef  PI-103 
128. Bottom: CEM cells expressing PTEN with either
eYFP (vector) or Nef-eYFP (Nef) were processed as
described above. MFI: vector  384, Nef  94.6, Nef 
2c  232, Nef  PI-103  162.
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from a signaling- to a stoichiometric-mode depended upon
the activity of the multi-kinase complex. To test this possi-
bility, replicate plates of H9 cells were infected with Nef or
Nef pseudotyped HIV-1 and then treated with 2c or PI-103
at 24 or 48 h postinfection. At 72 h postinfection, the level of
cell-surface MHC-I was analyzed by ﬂow cytometry, dem-
onstrating that addition of 2c or PI-103 for 24 or 48 h re-
pressed the ability of Nef to down-regulate MHC-I (supple-
mental Figure S7). Next, the cells were subjected to the
pulse-chase/surface biotinylation assay. In agreement with
the results in Figure 6 and the ﬂow cytometry results, Nef
expressed for 72 h repressed delivery of newly synthesized
MHC-I to the cell surface (Figure 7). By contrast, treatment
of the infected cells with either 2c or PI-103 for as little as
24 h before the pulse-chase/surface biotinylation pre-
vented Nef from blocking cell-surface delivery of MHC-I
(Figure 7, A and B, respectively). Together, these results
suggest that sustained PI3K signaling driven by the multi-
kinase complex is required for Nef-induced MHC-I down-
regulation to switch from a signaling to a stoichiometric
mode.
Figure 6. Nef-induced MHC-I down-regulation switches from a signaling to a stoichiometric mechanism. (A) H9 cells infected with Nef
or Nef pseudotyped HIV-1NL4-3 viruses (moi  2.3) for 24, 48, or 72 h and subjected to pulse-chase/surface biotinylation using HC10
associated MHC-I and quantiﬁed as described in Methods. Error bars represent the mean  SD from 3 independent experiments. Cell
viability was greater than 95% at each time point as measured by trypan blue exclusion and greater than 90% of the cells were infected with
each virus as determined by GFP staining. (B) Primary CD4 T-cells were processed and quantiﬁed as in panel A except using BB7.2 to IP
native MHC-I. (C) H9 cells were infected with Nef or Nef pseudotyped HIV-1NL4-3 viruses for 24 or 72 h, MHC-I was immunoprecipitated
with mAb HC10 as in A and then digested or not with Endo H as described in Methods. (D) H9 cells were infected with Nef or Nef
pseudotyped HIV-1NL4-3 viruses for 48 or 72 h and then treated or not with PI-103 (5 M) or 2c (20 M) for 16 h. Cells were incubated with
W6/32 (3 g/ml) for 30 min and then chased and processed for immunoﬂuorescence microscopy as described in the legend to Figure 4A.
Post-ﬁx: Total MHC-I was detected post-ﬁxation by staining the cells with K455. Scale bar, 10 m. (E) H9 cells were infected with Nef or
Nef pseudotyped HIV-1NL4-3 viruses for 48 or 72 h and analyzed for down-regulation of MHC-I as described in Methods. MFI: 48 h Nef 
341, 48 h Nef  110, 72 h Nef  302, 72 h Nef  125.
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We report that Nef directs a highly regulated program to
down-regulate MHC-I consisting of the sequential use of the
signaling and stoichiometric modes of action. During the
ﬁrst two days after infection, Nef uses the signaling mode to
down-regulate MHC-I. This mode requires the binding of
Nef to a Golgi region-localized SFK that it can directly
activate to assemble a multi-kinase complex that triggers
down-regulation of cell-surface MHC-I in CD4 T-cells. Us-
ing the small molecule inhibitor 2c to disrupt the Nef-SFK
interaction, we repressed HIV-1 mediated down-regulation
of cell-surface HLA-A2 in primary CD4 T-cells. This 2c-
sensitive signaling pathway is present in primary CD4
T-cells and in H9 cells, which are replete for PTEN and are
sensitive to inhibition of the multi-kinase complex. CEM
cells, however, lack PTEN and thus fail to phenocopy the
MHC-I down-regulation pathway used in primary CD4
T-cells. By three days postinfection, Nef switches to the
stoichiometric mode that prevents delivery of newly synthe-
sized MHC-I to the cell surface. Interference with formation
of the multi-kinase complex disrupts the temporally con-
trolled block in MHC-I transport, suggesting the Nef-di-
rected signaling and stoichiometric modes are causally
linked.
A systematic analysis of the steps underlying MHC-I
down-regulation suggests 2c selectively blocks Nef action
early in the down-regulation pathway at the binding of Nef
to SFKs, notably Hck, Lyn, or Src (Figure 1 and supplemen-
tal Figure S3). However, the ability of 2c to directly inhibit
Hck (or potentially other kinases upstream of class I PI3K),
albeit at higher concentrations, may also contribute to the
efﬁcacy of 2c. Our NMR studies show that 2c affects the
conformation of the N-terminal polyproline helix that binds
the RT loop of SH3 domains on SFKs, especially V74(Figure
1). Furthermore, the NMR data identify a potential 2c bind-
ing pocket, opposite the SH3 domain binding site, in which
2c induces signiﬁcant changes of the amide resonances sur-
rounding V146, which has been previously identiﬁed as es-
sential for Nef-Hck binding (Saksela et al., 1995). Interest-
ingly, 2c induces a change in the resonance at K144, which
must be ubiquitylated for Nef to down-regulate CD4 (Jin et
al., 2008). The lack of effect of 2c on HIV-1–induced CD4
down-regulation (Figure 2), however, suggests that ubiqui-
tylation of Nef K144 is unaffected by 2c. Together, these
studies suggest 2c may be a weak competitive inhibitor of
Nef-SFK binding or may induce an allosteric change in Nef
that indirectly represses binding to SFKs, explaining why
micromolar concentrations of 2c are required to inhibit
MHC-I down-regulation. In support of an allosteric mecha-
nism, Nef alleles from long-term nonprogressors that fail to
activate Hck exhibit mutations at a distance from the Hck
SH3 docking site on Nef (Trible et al., 2007). The ability of 2c
to only partially inhibit MHC-I down-regulation in plasmid
transfected cells may reﬂect a lower efﬁcacy of this inhibitor
compared with the class I PI3K inhibitor PI-103, which com-
pletely inhibits MHC-I down-regulation irrespective of the
vector used (compare Figures 2 and S7). However, 2c can
completely inhibit Nef-mediated MHC-I down-regulation in
pseudovirus-infected cells, suggesting length of treatment,
as well as the extent and duration of Nef expression, may
inﬂuence the efﬁcacy of this compound. The dialdehyde
moiety in 2c may also be subject to chemical inactivation by
reactive oxygen species characteristic of HIV-1 infection,
precluding maximal efﬁcacy of this inhibitor (Figure 2 and
supplemental Figure S2 and Peterhans, 1997). Nonetheless,
the ﬁndings reported here, together with the determination
that 2c represses the Nef-Hck-dependent down-regulation
of macrophage colony-stimulating factor (M-CSF) receptor
and that diphenylfuropyriminde compounds that selec-
tively block Nef-induced Hck activation also inhibit Nef-
dependent HIV-1 replication, suggest that the future gener-
ation of potent and selective drug-like molecules that
disrupt Nef-SFK binding may represent an attractive ap-
proach to the generation of novel HIV-1 therapeutics (Suzu
et al., 2005; Hiyoshi et al., 2008; Emert-Sedlak et al., 2009;
Hassan et al., 2009).
The signaling mode requires the PACS-2-dependent, Nef-
assembled SFK-ZAP-70/Syk-PI3K multi-kinase complex to
trigger increased internalization of cell-surface MHC-I mol-
ecules through an ARF6-regulated endocytic pathway
(Blagoveshchenskaya et al., 2002; Hung et al., 2007; Atkins et
al., 2008; Chaudhry et al., 2008). The internalized molecules
Figure 7. The PI3K signaling pathway is re-
quired for stoichiometric inhibition of MHC-I.
(A) H9 cells were infected with Nef or Nef
pseudotyped HIV-1NL4-3 viruses for a total of
72 h and either left untreated (control) or pre-
treated with 20 M 2c for 48 h (2c 48 h) or 24 h (2c
24 h) before analysis at 72 h postinfection. The
cells were then subjected to pulse-chase/surface
biotinylation as described in Methods. The
amount of HC10 associated MHC-I delivered to
the cell surface was quantiﬁed as described in
Methods. Error bars are presented as the mean 
SD from three independent experiments. (B) H9
cells were infected as above and left untreated
(control) or pretreated with 5 M PI-103 for 48 h
(PI-103 48 h) or 24 h (PI-103 24 h) before analysis
at 72 h postinfection and then processed as in
panel A. The amount of MHC-I delivered to the
cell surface was quantiﬁed as described in Meth-
ods. Error bars are presented as the mean  SD
from three independent experiments. (p/c), cells
treated with 20 M 2c (A) or 10 M PI-103 (B)
during the pulse-chase only.
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Nef M20-, AP-1–, and PACS-1–dependent process (Figure 4
and Blagoveshchenskaya et al., 2002; Chaudhry et al., 2008).
Thus, AP-1 is required for both the signaling and stoichio-
metric modes of MHC-I down-regulation, but whether
PACS-1 is also required in the stoichiometric mode or
whether PACS-1 and AP-1 mediate common or separate
sorting steps required for sequestering internalized MHC-I
molecules into TGN/endosomal compartments remains to
be determined. Nonetheless, these ﬁndings suggest the
PACS proteins mediate distinct steps within the signaling
pathway—the trigger phase (PACS-2) and the sequestering
phase (PACS-1). By three days postinfection, Nef switches to
a stoichiometric mode of down-regulation that prevents de-
livery of newly synthesized MHC-I molecules to the cell
surface. The ability of 2c or PI-103 to prevent conversion
from the signaling to stoichiometric mode suggests that
signaling events directed by one or more of the kinases
that form the multi-kinase complex may either result in
post-translational modiﬁcation of MHC-I, or may alter the
activity of the membrane trafﬁcking machinery that me-
diates the switch from the signaling to the stoichiometric
mode. The precise mechanism controlling the switch be-
tween the signaling and stoichiometric modes warrants
further investigation.
The relative contributions of the signaling and stoichio-
metric modes to Nef-induced MHC-I down-regulation have
been controversial, and discrepancies may have arisen from
different experimental designs, choice of cell lines, and in-
terpretation of negative results. For example, the signaling
mode was initially dismissed as a result of differences in the
efﬁciency by which Nef is able to impede cell surface deliv-
ery of MHC-I in T-cells versus HeLa cells (Kasper and
Collins, 2003; Kasper et al., 2005). By contrast, we determined
using parallel experiments that these differences instead re-
sult from the time postinfection at which MHC-I transport is
analyzed. During early times postinfection and continuing
for 48 h, Nef has no effect on the ER to cell surface transport
of endogenous MHC-I molecules in HeLa, H9, and primary
CD4 T-cells whereas by 72 h Nef can block MHC-I trans-
port (Figures 6 and 7 and Blagoveshchenskaya et al., 2002;
Hung et al., 2007). This bimodal mechanism of Nef-mediated
MHC-I down-regulation does not appear to result from
differences in Nef expression or in the antibodies used,
suggesting the modes of Nef action may be temporally
regulated. Second, the failure of PI3K inhibitors to block
MHC-I down-regulation in PTEN-deﬁcient Jurkat, CEM, or
U373 cells together with the confusion regarding regulation
of PTEN activity in leukemic cell lines was used to assert
that Nef mediates MHC-I down-regulation by a PI3K-inde-
pendent mechanism (Kasper and Collins, 2003; Larsen et al.,
2004; Schaefer et al., 2008). However, reexpression of PTEN
in CEM or U373 cells restored sensitivity of Nef-mediated
MHC-I down-regulation to 2c or PI3K inhibitors, whereas
siRNA knockdown of PTEN in H9 T-cells rendered Nef-
mediated MHC-I down-regulation resistant to PI3K inhibitors
(Figure 5 and Hung et al., 2007). Therefore, the determina-
tion that the mechanism of Nef-induced MHC-I down-reg-
ulation in primary CD4 T-cells is phenocopied by H9 cells
but not CEM cells underscores the importance of choice of
cell lines used to model Nef action (Figure 5). Thus, the
ability of PTEN-deﬁcient CEM and U373 tumor cells to
override the requirement for the SFK-ZAP-70/Syk-PI3K
multi-kinase complex in triggering Nef action likely explains
the confusion in the literature regarding the importance of
Nef sites in MHC-I down-regulation (Kasper and Collins,
2003; Larsen et al., 2004; Casartelli et al., 2006; Noviello et al.,
2008; Schaefer et al., 2008). For example, the assertion that
the AXXA75 mutation nonspeciﬁcally disrupts MHC-I
down-regulation in PTEN-null cells (Swann et al., 2001;
Casartelli et al., 2006) conﬂicts with the ability of NefAXXA-
PI3K* to rescue MHC-I down-regulation in H9 cells (Figure
4) and with the pharamacologic repression of MHC-I down-
regulation by treatment of primary CD4 T-cells with PI-
103, which inhibits class I PI3K, or with 2c or D1, which
block the Nef-SFK interaction (Betzi et al., 2007; Hung et al.,
2007; Hiyoshi et al., 2008; Emert-Sedlak et al., 2009 and
Figures 1 and 2). Reliance on PTEN-deﬁcient cell lines may
not only have caused confusion in understanding the mech-
anism of MHC-I down-regulation but may have also con-
tributed to conﬂicting ﬁndings in HIV-1 research ranging
from the signaling pathways that reactivate latent HIV-1 to
the secretion of HIV-1 Tat (Bosque and Planelles, 2009;
Rayne et al., 2010). Third, the failure of a dominant negative
dynamin mutant, which interferes with clathrin-dependent
endocytosis, to block MHC-I down-regulation was used to
suggest that Nef does not direct MHC-I endocytosis (Swann
et al., 2001). However, MHC-I is internalized by a clathrin/
dynamin/AP-2-independent, ARF6-dependent pathway—
both basally and in response to Nef (Le Gall et al., 2000;
Blagoveshchenskaya et al., 2002; Caplan et al., 2002;
Naslavsky et al., 2003; Hung et al., 2007; Chaudhry et al.,
2008). Fourth, the ability of GST-MHC-I CD-NefLL/AA to
bind AP-1 1 subunit in vitro was used to assert that Nef
does not require PACS-1 to down-regulate MHC-I in vivo
(Noviello et al., 2008; Singh et al., 2009). However, GST-
MHC-I CD-NefLL/AA can also interact with PACS-1 (Figure
4), contradicting the assumption by Guatelli et al. that this
bacterial fusion protein interacts exclusively with AP-1
(Singh et al., 2009). Instead, these protein capture data are
consistent with the determination in vivo that PACS-1 me-
diates Nef-induced MHC-I down-regulation subsequent to
PI3K stimulation (Figure 4 and Atkins et al., 2008; see also
Youker et al., 2009 for review). Lastly, whereas Nef can
induce rapid degradation of overexpressed MHC-I (Kasper
and Collins, 2003; Roeth et al., 2004; Kasper et al., 2005;
Schaefer et al., 2008), we observed no marked effect on the
stability or ER-to-Golgi trafﬁcking of endogenous MHC-I
(Figure 6 and supplemental Figure S6 and Blagoveshchen-
skaya et al., 2002; Hung et al., 2007). Thus, the extent to which
overexpressed HLA-A2.1 is physiologically relevant to the
mechanism underlying Nef-induced MHC-I down-regula-
tion remains unclear.
The determination that Nef down-regulates MHC-I by the
sequential use of the signaling mode followed by the stoi-
chiometric mode raises the possibility that HIV-1 may adapt
immune evasive strategies speciﬁc to the host cell activation
state or reservoir type. Because the lifespan of activated
CD4 T-cells infected with HIV-1 is less than two days
(Stevenson, 2003), and Nef uses the signaling mode to down-
regulate MHC-I in CD4 T-cells for two days before con-
verting to the stoichiometric mode (Figures 6 and 7), the
physiological relevance of the stoichiometric pathway in
activated CD4 T-cells remains uncertain. However, Nef
also assembles the multi-kinase complex in cells of mono-
cyte lineages, of which macrophages produce a low but
persistent level of virus that can last the duration of the cell’s
natural lifespan (Hung et al., 2007; Alexaki et al., 2008).
Future studies on the immune evasive program directed by
HIV-1 Nef will require membrane trafﬁcking experiments in
relevant cell lines to determine the relative contributions of
the signaling and stoichiometric modes of Nef action. The
physiological signiﬁcance of Nef’s bimodal MHC-I down-
regulation pathway in viral reservoirs can then be correlated
J. D. Dikeakos et al.
Molecular Biology of the Cell 3290to disease progression. Finally, the ability of 2c and other
small molecules to repress multiple actions of Nef suggests
the multi-kinase complex may be an attractive approach for
HIV-1 therapeutics.
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